

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

GRANT OF SHARE AWARDS

GRANT OF SHARE AWARDS

On a voluntary basis, the Board announces that on 22 June 2021, the Company granted 1,881,357 Awards to 106 Grantees under the Post-IPO Share Award Scheme and granted 1,077,600 Awards to 49 Grantees under the Pre-IPO ESOP.

Each of the Awards is granted, among other terms, for nil consideration, and represents the right to receive one Share on the date the Award vests.

The market price of the Shares on the date of grant was HK\$70.50 per Share.

None of the grant of Awards will be subject to approval by the Shareholders, and none of the Grantees is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company or an associate (as defined in the Listing Rules) of any of them.

The Post-IPO Share Award Scheme and the Pre-IPO ESOP does not constitute a share option scheme pursuant to Chapter 17 of the Listing Rules and is a discretionary scheme of the Company.

The grant of Awards enable the Company to attract, retain, incentivize, reward and remunerate the Grantees, and encourage them to work towards enhancing the value of the Company and the Shares for the benefit of the Company and Shareholders as a whole.

DEFINITIONS

“Award(s)” awards(s), being a contingent right to receive Shares awarded under the Post-IPO Share Award Scheme and the Pre-IPO ESOP

“Board” the board of Directors

“Company”	Everest Medicines limited, an exempted company with limited liability incorporated in the Cayman Islands on 14 July 2017
“Directors”	the directors of the Company
“Grantees”	the employees of the Company and its subsidiaries who were granted Awards in accordance with the Post-IPO Share Award Scheme and/or the Pre-IPO ESOP on 22 June 2021
“HK\$”	Hong Kong dollar, the lawful currency of the Hong Kong Special Administrative Region of the People’s Republic of China
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“Post-IPO Share Award Scheme”	the post-IPO share award scheme adopted by the Shareholders on 21 September 2020
“Pre-IPO ESOP”	the pre-IPO employee equity plan adopted on 25 December 2018, amended and restated on 17 February 2020, which terminated in relation to options upon the listing of the Company but not restricted stock units (as defined therein)
“Shareholders”	holder(s) of Shares in the Company
“Shares”	ordinary shares in the share capital of the Company with a par value of US\$0.0001 each
“US\$”	U.S dollars, the lawful currency of the United States of America

By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 22 June 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.